Dr. Andrew Scharenberg, M.D., to Serve as Chief Scientific Officer for Cellectis therapeutics

PARIS, July 11, 2011 /PRNewswire/ -- Cellectis therapeutics, a subsidiary of Cellectis (Alternext: ALCLS) specializing in the development of therapeutic applications in genome engineering, today announced the appointment of Dr. Andrew M. Scharenberg as Chief Scientific Officer.

Dr. Scharenberg is an attending physician in Immunology at Seattle Children's Hospital, and Professor of Pediatrics and Immunology at the University of Washington. His academic laboratory is based at Seattle Children's Research Institute, and is world renowned for its work on the development of genome engineering technologies for innovative therapeutic applications.

Dr. Scharenberg is a principal investigator and codirector of the Northwest Genome Engineering Consortium (NGEC), which is focused on new approaches for treating genetic diseases. In addition, he is a cofounder and member of the Board of Director's of Pregenen Inc., a biotechnology spin-off from the NGEC, and a strategic partner of Cellectis focused on the commercial development of novel genome engineering technologies.

"We are thrilled that Andrew Scharenberg has accepted the post of Chief Scientific Officer of our therapeutic subsidiary," stated Chief Scientific Officer of the Cellectis group Frederic Paques. "His experience and energy will push our research teams to achieve their full potential."

About Cellectis therapeutics

Founded in 2008, Cellectis therapeutics is dedicated to the development of innovative therapeutic approaches that use meganucleases to treat genetic diseases, cancers, and persistent viral infections. Its prospective treatment targets the DNA sequence that causes disease, which may be innate (genetic disease) or acquired (viral infection, cancer). Cellectis therapeutics' aim is to fulfill unmet medical needs, giving patients new hope.

About Cellectis

Cellectis improves life by applying its genome engineering expertise to a broad range of applications, including agriculture, bioresearch and human therapeutics. Cellectis is listed on the NYSE-Euronext Alternext market (code: ALCLS) in Paris.

For further information about Cellectis, visit our website at: www.cellectis.com

Follow Cellectis on twitter : http://twitter.com/cellectis

Disclaimer

This press release and the information contained herein do not constitute an offer to sell or subscribe, or a solicitation of an offer to buy or subscribe, for shares in Cellectis in any country. This press release contains forward-looking statements that relate to the Company's objectives based on the current expectations and assumptions of the Company's management only and involve risk and uncertainties that could cause the Company to fail to achieve the objectives expressed by the forward-looking statements above.

SOURCE Cellectis

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED